

<ul style="list-style-type: none"> • Review today's agenda • Review action item from last meeting - see attachment 2 	
STANDING ITEMS	Topic
A) Activity streams	
0. New or updated syntheses	
<ul style="list-style-type: none"> • Intake and prioritization <i>(includes intake for living docs)</i> 	<ul style="list-style-type: none"> • Status of requests and completed products - updated format • An increased volume of requests is expected going forward now that key presentations have been made to PHAC and the Government of Canada more generally
<ul style="list-style-type: none"> • Rapid evidence profiles (REPs) 	<ul style="list-style-type: none"> • See status link above
<ul style="list-style-type: none"> • Rapid evidence syntheses (RSs) 	<ul style="list-style-type: none"> • See status link above
<ul style="list-style-type: none"> • Plain language summaries <i>(includes summaries for living documents below)</i> 	<ul style="list-style-type: none"> • Procedures document and summary template completed; first set of eight plain language summaries (PLS) completed; next steps: translation, posting on website
1. Living evidence syntheses	
<ul style="list-style-type: none"> • Living evidence profiles 	<ul style="list-style-type: none"> • See status link above
<ul style="list-style-type: none"> • Living evidence syntheses 	<ul style="list-style-type: none"> • Update about addressing a complex question about the efficacy and effectiveness of COVID-19 vaccines on variants of concern (VOC) <ul style="list-style-type: none"> • There are 4 groups in the world maintaining living syntheses about the <u>efficacy</u> of vaccines based on randomized trials, but we could not find any groups maintaining living evidence syntheses of all the observational studies to give us insights on effects on VOC. • Our response will be available on the ‘Scan evidence products’ page of the COVID-END in Canada section of the website. • In addition, we are developing a framework to understand what we currently know about effectiveness, and we will be providing once per week a report based on observational studies (work being led by Alfonso Iorio from McMaster University and Julian Little from the University of Ottawa)
<ul style="list-style-type: none"> • Other 	<ul style="list-style-type: none"> •
2. Inventory of ‘best evidence syntheses’	
<ul style="list-style-type: none"> • Status 	<ul style="list-style-type: none"> • 6,496 syntheses from high-quality/high-yield sources → 5,136 non-duplicate syntheses → 3,522 decision-relevant syntheses → 385 ‘best’ evidence syntheses (updated 1 Apr) • Additional field(s) for equity considerations being added
<ul style="list-style-type: none"> • Searchable database 	<ul style="list-style-type: none"> • Expected by end of May
<ul style="list-style-type: none"> • Inventory spotlights 	<ul style="list-style-type: none"> • Canadian (see below) and global inventory spotlights
3. Evidence-demand coordination	
<ul style="list-style-type: none"> • Canadian Public Health Network (SAC and TAC) 	<ul style="list-style-type: none"> • Presentation to SAC completed
<ul style="list-style-type: none"> • Other PHAC (Chief Science Officer, CPTG), other 	<ul style="list-style-type: none"> •
<ul style="list-style-type: none"> • Other federal government 	<ul style="list-style-type: none"> • Presentation to Government of Canada representatives
<ul style="list-style-type: none"> • Provincial and territorial governments 	<ul style="list-style-type: none"> • Review list of provincial and territorial government contacts and solicit additional suggestions to help reach the right people with the right information available from our network - see attachment 3 • ACTION: Everyone to review the list and provide additional suggestions to Sarah Weberman or directly to covidend@mcmaster.ca email
<ul style="list-style-type: none"> • Tracking 	<ul style="list-style-type: none"> •

<ul style="list-style-type: none"> • Webinars (and presentations) 	<ul style="list-style-type: none"> • One training webinar with evidence-synthesis teams Conducting rapid reviews for health system decision-makers through COVID-END - completed 16 February • One webinar with patient partners Navigating new waters together: Patient/citizen engagement in COVID-19 evidence synthesis - completed 23 February • Presentation to Special Advisory Committee (SAC) - completed 18 March • Quarterly meeting of the evidence-synthesis teams, with presentations about <i>lessons learned from preparing a complex living review (on VOC)</i> and <i>lessons learned from recruiting and onboarding citizen partners</i> - completed 29 March • Presentation to Government of Canada officials – completed 31 March
4. Horizon scanning	
<ul style="list-style-type: none"> • Adjustments to existing process 	<ul style="list-style-type: none"> • Horizon scans are published once a month and include a briefing note about emerging issues, and a panel summary about priority issues for Canada. • Next meeting is in April and will be continuing monthly (there was no meeting in March), complementing the global panel with deliberations specific to Canada. Canadian panelists have the option of observing the global meeting.
<ul style="list-style-type: none"> • Canadian panel membership 	<ul style="list-style-type: none"> • 8 confirmed, waiting to hear from 17 more invited
5. Evidence-supply coordination	
<ul style="list-style-type: none"> • Evidence-synthesis teams 	<ul style="list-style-type: none"> • Resources for researchers webpage • ACTION/REMINDERS to evidence-synthesis teams to please: <ul style="list-style-type: none"> • complete survey regarding areas of expertise • share with the secretariat relevant work that you took on, and work completed. • consult the global inventory and the (soon to be made available to our network partners) searchable Excel database of Canadian documents. • Everyone can feel free to send an email to the secretariat at covidend@mcmaster.ca if they need help with the searches on the inventory of best evidence (especially before May 20th when the searchable inventory functionality will be available online) or with searches for Canadian documents. • ACTION: secretariat to post the Excel database of Canadian documents on a web section available only to network members and inform the collaborators group about where it is located
<ul style="list-style-type: none"> • Canadian synthesis spotlights 	<ul style="list-style-type: none"> • Canadian spotlights can be accessed here
<ul style="list-style-type: none"> • Dissemination vehicles 	<ul style="list-style-type: none"> • Subscription functionality implemented (subscribe here) • Canadian COVID-19 email update provides three types of products from COVID-END in Canada: <ol style="list-style-type: none"> 1) Canadian spotlights, 2) global spotlights, and 3) horizon scans • Outputs are also captured by the government of Canada into the email going out across the public service federally. This supports the access by Chief medical officers of health across the country to both global and Canadian-specific content • For future consideration: ability to implement a mechanism to track the uptake this information among the target audience. • Update about other dissemination vehicles
B) Cross-cutting	
<ol style="list-style-type: none"> 1. Citizen partnership 	<ul style="list-style-type: none"> • Update: Planning and recruitment of citizen partners completed: 20 selected out of 80 candidates • Citizen partners on-boarding webinar - planned for week of 5 April • Citizen partners training mini-course - planned for month of May. • ACTIOM: Maureen to contact Doris who offered to help with the recruitment of citizen partners to fill in any gaps.
<ol style="list-style-type: none"> 2. Indigenous peoples engagement 	
<ol style="list-style-type: none"> 3. Website and communications 	<ul style="list-style-type: none"> • Website content completed - see right-side tab ‘Resources Specific to Canada’ www.covid-end.org (walk-through)
<ol style="list-style-type: none"> 4. Measuring impact 	<ul style="list-style-type: none"> •
OTHER BUSINESS / ARISING ISSUES	

<p>1. Brief updates about other relevant initiatives underway in Canada</p>	<ul style="list-style-type: none"> • CIHR national networks: of COVID-19 trialists, data modelers, and newly announced Coronavirus Variants Rapid Response Network (CoVaRR) • 19 to Zero network focused on COVID-19 behaviors and vaccination • Others? • Outline of <u>CoVaRR</u> (Jeremy) <ul style="list-style-type: none"> • The CIHR-funded network focusses on identification and characteristics of variants of concerns' health system and public health system impacts • Funding resources may be available to maintain the living syntheses work being done by Janet Curran (Dalhousie) on public health and health systems implications of VOC and by Julian Little and Alfonso Iorio (on vaccine effectiveness, as mentioned above) • ACTION: secretariat and Co-PIs of both networks to discuss a direct collaboration of the two networks • Maureen offered to add information in the NCCMT monthly newsletter which reaches 15,000+ public health decision as it becomes available. • Network of <u>COVID Trials Networks</u> keen to feed into (and benefit from) COVID END. ◦ ACTION: Secretariat to connect with Rob Fowler • <u>CMAJ Open</u> has a patient-oriented research working on a 'special collection' of content, looking for opportunities to publish content related to patient-engagement. Simon is part of the advisory group with the editor-in-chief <ul style="list-style-type: none"> • For future consideration by the CO-PIs and citizen partnership co-leads
<p>2. Next meeting</p>	<ul style="list-style-type: none"> • Thursday 3 June